在药物研发与评价中纳入功能指标与衰弱评估
该卫生政策文章指出,自1994年ICH E7指南发布以来,老年人在临床试验中的纳入情况几乎未有改善,尤其75岁以上人群。文章从临床医生和监管机构两个视角提出八条建议,旨在改善对衰弱老年人所用药物的关键评价与监管审查。
要点
- ICH E7指南自1994年至今,老年人临床试验纳入改善甚微。
- 75岁以上人群是欧盟增长最快的人口组,但相关终点与安全性结局罕有报告。
- 文章提出八条建议,需多方利益相关者共同实施。
核心结论
- 改善衰弱老年人临床试验纳入需要意识、聚焦与行动,非单一实体能独立完成。
研究设计与样本
- 本文为卫生政策类文章,基于临床医生与监管机构的不同视角和经验提出建议。
主要发现
- 自1994年ICH E7发布以来,老年人临床试验纳入几乎未改善,尤其75岁以上人群。
- 多数药物由该人群服用,但临床试验和监管审批文件中罕有报告该队列的相关终点和安全性结局。
关键数值与推荐
- 文章提出八条建议,涉及改善衰弱老年人所用药物的关键评价与监管审查。
临床怎么用
- 建议适用于利益相关者、监管当局、制药公司和研究人员,需多方协同实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E7, the guidance for the conduct of clinical trials in people older than age 65 years, dates from 1994. Since then, the inclusion of older people in clinical trials has hardly improved, particularly for the oldest old age group (individuals older than age 75 years), which is the fastest growing demographic bracket in the EU. Even though most medications are taken by this group, relevant endpoints and safety outcomes for this cohort are rarely included and reported, both in clinical trials and regulatory approval documents. To improve the critical appraisal and the regulatory review of medicines taken by frail older adults, eight recommendations are presented and discussed in this Health Policy. These recommendations are brought together from different perspectives and experience of the treatment of older patients. On one side, the perspective of medical practitioners from various clinical disciplines, with their direct experience of clinical decision making; on the other, the perspective of regulators assessing the data submitted in medicine registration dossiers, their relevance to the risk-benefit balance for older patients, and the communication of the findings in the product information. Efforts to improve the participation of older people in clinical trials have been in place for more than a decade, with little success. The recommendations presented here are relevant for stakeholders, authorities, pharmaceutical companies, and researchers alike, as the implementation of these measures is not under the capacity of a single entity. Improving the inclusion of frail older adults requires awareness, focus, and action on the part of those who can effect a much needed change.
引用
- Denkinger M, Knol W, Cherubini A, et al. Inclusion of functional measures and frailty in the development and evaluation of medicines for older adults. Lancet Healthy Longev. 2023. PMID: 37977177. doi:10.1016/S2666-7568(23)00208-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。